RIP1 activates PI3K-Akt via a dual mechanism involving NF-κB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN

Cancer Research

Volumn 69, Issue 10, 2009, Pages 4107-4111

  Park, Seongmi ^a   Zhao, Dawen ^a,b   Hatanpaa, Kimmo J ^a   Mickey, Bruce E ^a   Saha, Debabrata ^a   Boothman, David A ^b   Story, Michael D ^a   Wong, Eric T ^c   Burma, Sandeep ^a   Georgescu, Maria Magdalena ^d   Rangnekar, Vivek M ^e   Chauncey, Sandili S ^a   Habib, Amyn A ^a,f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; GLIOBLASTOMA; HUMAN; HUMAN CELL; NEGATIVE FEEDBACK; PRIORITY JOURNAL; TREATMENT RESPONSE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BRAIN NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; NF-KAPPA B; NUCLEAR PORE COMPLEX PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA-BINDING PROTEINS;

EID: 66249138523     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0474     Document Type: Article

References (20)

1. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
2. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133:403-414
3. Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 2005;30:35-42. (Pubitemid 40093739)
4. McDonald PC, Oloumi A, Mills J, et al. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 2008;68:1618-1624
5. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-183 (Pubitemid 41317589)
6. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008;5:e8.
7. Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995;81:513-523
8. Grimm S, Stanger BZ, Leder P. RIP and FADD: two "death domain"-containing proteins can induce apoptosis by convergent, but dissociable, pathways. Proc Natl Acad Sci U S A 1996;93:10923-10927
9. Park S, Ramnarain DB, Hatanpaa KJ, et al. The death domain-containing kinase RIP1 regulates p27(Kip1) levels through the PI3K-Akt-forkhead pathway. EMBO Rep 2008;9:766-773
10. Vivarelli MS, McDonald D, Miller M, Cusson N, Kelliher M, Geha RS. RIP links TLR4 to Akt and is essential for cell survival in response to LPS stimulation. J Exp Med 2004;200:399-404. (Pubitemid 39031258)
11. Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci 2005;30:151-159 (Pubitemid 40332531)
12. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007;14:400-410 (Pubitemid 46259948)
13. Pimentel-Muinos FX, Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999;11:783-793 (Pubitemid 30030717)
14. Chang L, Kamata H, Solinas G, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIP(L) turnover. Cell 2006;124:601-613
15. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 2004;6:297-305. (Pubitemid 39222042)
16. Park S, Hatanpaa KJ, Xie Y, et al. The receptor interacting protein 1 inhibits p53 induction through nuclear factor-κB activation and confers a worse prognosis in glioblastoma. Cancer Res 2009;69:2809-2816
17. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-κB prevents apoptosis. Mol Cell Biol 2004;24:1007-1021 (Pubitemid 38112166)
18. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006;65:1181-1188
19. Dan HC, Baldwin AS. Differential involvement of IκB kinases α and β in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol 2008;180:7582-7589
20. Lee DF, Kuo HP, Chen CT, et al. IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007;130:440-455 (Pubitemid 47198298)